Observation is effective in the management of haemangioma of infancy.

Article

Using a combination of observation and amblyopia therapy is successful in mild cases of periocular haemangioma of infancy (HOI).

An investigation published in the Journal of Paediatric Ophthalmology and Strabismus has demonstrated that using a combination of observation and amblyopia therapy is successful in mild cases of periocular haemangioma of infancy (HOI).

Dr Assad Jalil et al., Manchester Royal Eye Hospital, Manchester, UK, conducted a retrospective study on 41 children. The children were divided into groups according to treatment methods. This included observation, intralesional steroid injections (ILSI), and oral steroids.

Of the children included in the research, 24 had amblyopia at presentation, 18 children were in the observation group, 17 were administered ILSI and 6 children were given oral steroids.

Success was measured when HOI regression was completed before the child was 5 years of age (cosmetic group), astigmatism was reduced by 1 dioptre cylinder (DC) (astigmatism group) or if there was no evidence of amblyopia at the last follow-up (visual axis obscuration group).

The cosmetic group demonstrated a high success rate, with all but 2 patients treated. The visual axis obscuration group saw 6 of 7 patients treated.

Mean astigmatic correction of the patients was 1.65 ± 1.34 DC pre-treatment and 0.91 ± 1.17 DC post-treatment. This proved to be statistically significant and proved that, as well as observation, ILSI and oral steroids can be effective for treating lesions. However, their role has not been completely determined with regards to spontaneously resolving lesions.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.